Farnesylthiosalicylic	B:C0297002
acid	I:C0297002
-	O
loaded	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
for	O
treatment	O
of	O
glioblastoma	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
lipid	B:C1254351
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
for	O
treatment	O
of	O
glioblastoma	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
for	O
treatment	B:C0087111
of	O
glioblastoma	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
for	O
treatment	O
of	O
glioblastoma	B:C0017636
.	O

We	O
aimed	O
to	O
develop	O
lipid	B:C1254351
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	B:C0475358
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	B:C1372955
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	B:C0003392
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	B:C0297002
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	B:C0297002
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	B:C0087111
of	O
glioblastoma	O
.	O

We	O
aimed	O
to	O
develop	O
lipid	O
-	I:C1254351
polyethylene	I:C1254351
glycol	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
polymer	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
,	O
which	O
have	O
high	O
affinity	O
to	O
tumour	O
tissue	I:C0475358
with	O
active	O
ingredient	I:C1372955
,	O
a	O
new	O
generation	O
antineoplastic	O
drug	I:C0003392
,	O
farnesylthiosalicylic	O
acid	I:C0297002
(	O
farnesylthiosalicylic	O
acid	I:C0297002
)	O
for	O
treatment	O
of	O
glioblastoma	B:C0017636
.	O

Farnesylthiosalicylic	B:C0297002
acid	I:C0297002
-	O
loaded	O
poly	O
(	I:C1254351
lactic	I:C1254351
-	I:C1254351
co	I:C1254351
-	I:C1254351
glycolic	I:C1254351
acid	I:C1254351
)	I:C1254351
-	I:C1254351
1,2	I:C1254351
distearoyl	I:C1254351
-	I:C1254351
glycerol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
phospho	I:C1254351
-	I:C1254351
ethanolamine	I:C1254351
-	I:C1254351
N	I:C1254351
[	I:C1254351
methoxy	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
2000	I:C1254351
]	I:C1254351
ammonium	I:C1254351
salt	I:C1254351
(	O
PLGA	O
-	I:C1254351
DSPE	I:C1254351
-	I:C1254351
PEG	I:C1254351
)	O
with	O
or	O
without	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
(	I:C1254351
DOTAP	I:C1254351
)	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
poly	B:C1254351
(	I:C1254351
lactic	I:C1254351
-	I:C1254351
co	I:C1254351
-	I:C1254351
glycolic	I:C1254351
acid	I:C1254351
)	I:C1254351
-	I:C1254351
1,2	I:C1254351
distearoyl	I:C1254351
-	I:C1254351
glycerol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
phospho	I:C1254351
-	I:C1254351
ethanolamine	I:C1254351
-	I:C1254351
N	I:C1254351
[	I:C1254351
methoxy	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
2000	I:C1254351
]	I:C1254351
ammonium	I:C1254351
salt	I:C1254351
(	O
PLGA	O
-	I:C1254351
DSPE	I:C1254351
-	I:C1254351
PEG	I:C1254351
)	O
with	O
or	O
without	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
(	I:C1254351
DOTAP	I:C1254351
)	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
poly	O
(	I:C1254351
lactic	I:C1254351
-	I:C1254351
co	I:C1254351
-	I:C1254351
glycolic	I:C1254351
acid	I:C1254351
)	I:C1254351
-	I:C1254351
1,2	I:C1254351
distearoyl	I:C1254351
-	I:C1254351
glycerol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
phospho	I:C1254351
-	I:C1254351
ethanolamine	I:C1254351
-	I:C1254351
N	I:C1254351
[	I:C1254351
methoxy	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
2000	I:C1254351
]	I:C1254351
ammonium	I:C1254351
salt	I:C1254351
(	O
PLGA	B:C1254351
-	I:C1254351
DSPE	I:C1254351
-	I:C1254351
PEG	I:C1254351
)	O
with	O
or	O
without	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
(	I:C1254351
DOTAP	I:C1254351
)	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
poly	O
(	I:C1254351
lactic	I:C1254351
-	I:C1254351
co	I:C1254351
-	I:C1254351
glycolic	I:C1254351
acid	I:C1254351
)	I:C1254351
-	I:C1254351
1,2	I:C1254351
distearoyl	I:C1254351
-	I:C1254351
glycerol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
phospho	I:C1254351
-	I:C1254351
ethanolamine	I:C1254351
-	I:C1254351
N	I:C1254351
[	I:C1254351
methoxy	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
2000	I:C1254351
]	I:C1254351
ammonium	I:C1254351
salt	I:C1254351
(	O
PLGA	O
-	I:C1254351
DSPE	I:C1254351
-	I:C1254351
PEG	I:C1254351
)	O
with	O
or	O
without	O
1,2	B:C1254351
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
(	I:C1254351
DOTAP	I:C1254351
)	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
has	O
been	O
prepared	O
and	O
evaluated	O
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
poly	O
(	I:C1254351
lactic	I:C1254351
-	I:C1254351
co	I:C1254351
-	I:C1254351
glycolic	I:C1254351
acid	I:C1254351
)	I:C1254351
-	I:C1254351
1,2	I:C1254351
distearoyl	I:C1254351
-	I:C1254351
glycerol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
phospho	I:C1254351
-	I:C1254351
ethanolamine	I:C1254351
-	I:C1254351
N	I:C1254351
[	I:C1254351
methoxy	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
2000	I:C1254351
]	I:C1254351
ammonium	I:C1254351
salt	I:C1254351
(	O
PLGA	O
-	I:C1254351
DSPE	I:C1254351
-	I:C1254351
PEG	I:C1254351
)	O
with	O
or	O
without	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
(	I:C1254351
DOTAP	I:C1254351
)	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
has	O
been	O
prepared	B:C4082130
and	O
evaluated	O
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
poly	O
(	I:C1254351
lactic	I:C1254351
-	I:C1254351
co	I:C1254351
-	I:C1254351
glycolic	I:C1254351
acid	I:C1254351
)	I:C1254351
-	I:C1254351
1,2	I:C1254351
distearoyl	I:C1254351
-	I:C1254351
glycerol	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
phospho	I:C1254351
-	I:C1254351
ethanolamine	I:C1254351
-	I:C1254351
N	I:C1254351
[	I:C1254351
methoxy	I:C1254351
(	I:C1254351
PEG	I:C1254351
)	I:C1254351
-	I:C1254351
2000	I:C1254351
]	I:C1254351
ammonium	I:C1254351
salt	I:C1254351
(	O
PLGA	O
-	I:C1254351
DSPE	I:C1254351
-	I:C1254351
PEG	I:C1254351
)	O
with	O
or	O
without	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
(	I:C1254351
DOTAP	I:C1254351
)	I:C1254351
hybrid	I:C1254351
nanoparticles	I:C1254351
has	O
been	O
prepared	O
and	O
evaluated	B:C0220825
for	O
in	O
-	O
vitro	O
characterization	O
.	O

Cytotoxicity	B:C0596402
of	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma	I:C0007634
-	I:C0007634
2	I:C0007634
(	I:C0007634
RG2	I:C0007634
)	I:C0007634
cells	I:C0007634
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	I:C0007600
line	I:C0007600
,	I:C0007600
L929	I:C0007600
)	O
and	O
in	O
vivo	O
.	O

Cytotoxicity	O
of	O
FTA	B:C0297002
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma	I:C0007634
-	I:C0007634
2	I:C0007634
(	I:C0007634
RG2	I:C0007634
)	I:C0007634
cells	I:C0007634
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	I:C0007600
line	I:C0007600
,	I:C0007600
L929	I:C0007600
)	O
and	O
in	O
vivo	O
.	O

Cytotoxicity	O
of	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
along	O
with	O
its	O
efficacy	O
on	O
rat	B:C0007634
glioma	I:C0007634
-	I:C0007634
2	I:C0007634
(	I:C0007634
RG2	I:C0007634
)	I:C0007634
cells	I:C0007634
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	I:C0007600
line	I:C0007600
,	I:C0007600
L929	I:C0007600
)	O
and	O
in	O
vivo	O
.	O

Cytotoxicity	O
of	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma	I:C0007634
-	I:C0007634
2	I:C0007634
(	I:C0007634
RG2	I:C0007634
)	I:C0007634
cells	I:C0007634
was	O
also	O
evaluated	B:C0220825
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	O
cell	I:C0007600
line	I:C0007600
,	I:C0007600
L929	I:C0007600
)	O
and	O
in	O
vivo	O
.	O

Cytotoxicity	O
of	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
along	O
with	O
its	O
efficacy	O
on	O
rat	O
glioma	I:C0007634
-	I:C0007634
2	I:C0007634
(	I:C0007634
RG2	I:C0007634
)	I:C0007634
cells	I:C0007634
was	O
also	O
evaluated	O
both	O
in	O
vitro	O
(	O
in	O
comparison	O
with	O
non-malignant	B:C0007600
cell	I:C0007600
line	I:C0007600
,	I:C0007600
L929	I:C0007600
)	O
and	O
in	O
vivo	O
.	O

Scanning	B:C0523160
electron	I:C0523160
microscopy	I:C0523160
studies	I:C0523160
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	O
surface	I:C1182795
and	O
spherical	O
in	I:C0332501
shape	I:C0332501
.	O

Scanning	O
electron	I:C0523160
microscopy	I:C0523160
studies	I:C0523160
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	B:C1182795
surface	I:C1182795
and	O
spherical	O
in	I:C0332501
shape	I:C0332501
.	O

Scanning	O
electron	I:C0523160
microscopy	I:C0523160
studies	I:C0523160
showed	O
that	O
all	O
formulations	O
prepared	O
had	O
smooth	O
surface	I:C1182795
and	O
spherical	B:C0332501
in	I:C0332501
shape	I:C0332501
.	O

farnesylthiosalicylic	B:C0297002
acid	I:C0297002
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
have	O
cytotoxic	O
activity	I:C0596402
against	O
RG2	O
glioma	I:C0007600
cell	I:C0007600
lines	I:C0007600
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
.	O

farnesylthiosalicylic	O
acid	I:C0297002
and	O
FTA	B:C0297002
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
have	O
cytotoxic	O
activity	I:C0596402
against	O
RG2	O
glioma	I:C0007600
cell	I:C0007600
lines	I:C0007600
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
.	O

farnesylthiosalicylic	O
acid	I:C0297002
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
have	O
cytotoxic	B:C0596402
activity	I:C0596402
against	O
RG2	O
glioma	I:C0007600
cell	I:C0007600
lines	I:C0007600
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
.	O

farnesylthiosalicylic	O
acid	I:C0297002
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
have	O
cytotoxic	O
activity	I:C0596402
against	O
RG2	B:C0007600
glioma	I:C0007600
cell	I:C0007600
lines	I:C0007600
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
1,2	O
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
.	O

farnesylthiosalicylic	O
acid	I:C0297002
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
have	O
cytotoxic	O
activity	I:C0596402
against	O
RG2	O
glioma	I:C0007600
cell	I:C0007600
lines	I:C0007600
in	O
cell	O
culture	O
studies	O
,	O
which	O
further	O
increases	O
with	O
addition	O
of	O
1,2	B:C1254351
-	I:C1254351
dioleoyl	I:C1254351
-	I:C1254351
3	I:C1254351
-	I:C1254351
trimethylammonium	I:C1254351
-	I:C1254351
propane	I:C1254351
.	O

Magnetic	B:C0024485
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	B:C0677043
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	B:C0220825
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	B:C0431085
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	B:C0012644
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	B:C0034716
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	B:C1254351
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	B:C0297002
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	O
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Magnetic	O
resonance	I:C0024485
imaging	I:C0024485
and	O
histopathologic	O
evaluation	O
on	O
RG2	O
tumour	I:C0431085
cells	I:C0431085
in	O
rat	O
glioma	I:C0012644
model	I:C0012644
(	O
49	O
female	O
Wistar	O
rats	I:C0034716
,	O
250	O
-	O
300	O
g	O
)	O
comparing	O
intravenous	O
and	O
intratumoral	O
injections	O
of	O
the	O
drug	O
have	O
been	O
performed	O
and	O
FTA	O
-	I:C0297002
loaded	I:C0297002
nanoparticles	I:C0297002
reduced	O
tumour	B:C0475440
size	I:C0475440
significantly	O
in	O
in	O
-	O
vivo	O
studies	O
,	O
with	O
higher	O
efficiency	O
of	O
intratumoral	O
administration	O
than	O
intravenous	O
route	O
.	O

Farnesylthiosalicylic	B:C0297002
acid	I:C0297002
-	O
loaded	O
PLGA	O
-	I:C1254351
DSPE	I:C1254351
-PEG	I:C1254351
-DOTAP	I:C1254351

Farnesylthiosalicylic	O
acid	I:C0297002
-	O
loaded	O
PLGA	B:C1254351
-	I:C1254351
DSPE	I:C1254351
-PEG	I:C1254351
-DOTAP	I:C1254351

hybrid	I:C1254351
nanoparticles	I:C1254351
are	O
proven	O
to	O
be	O
effective	O
against	O
glioblastoma	B:C0017636
in	O
both	O
in	O
-	O
vitro	O
and	O
in	O
-vivo	O
experiments	O
.	O

